OncLive SOSS (@onclivesoss) 's Twitter Profile
OncLive SOSS

@onclivesoss

Premier oncology summits that focus on the most relevant cancer topics to ultimately improve patient care. #OncLiveIPC

ID: 824013573873668096

linkhttp://www.onclive.com/meetings/soss calendar_today24-01-2017 21:58:40

25,25K Tweet

2,2K Takipçi

717 Takip Edilen

OncLive SOSS (@onclivesoss) 's Twitter Profile Photo
OncLive SOSS
@onclivesoss

3 years ago

Benjamin Heyman, MD, of UCSD Health Moores Cancer Center CRCERA, discusses the phase 3 SYMPATICO trial examining the combination of ibrutinib and venetoclax vs ibrutinib alone in patients with relapsed or refractory mantle cell lymphoma #lymsm bit.ly/3tk0h5v

Benjamin Heyman, MD, of <a href="/UCSDCRCERA/">UCSD Health Moores Cancer Center CRCERA</a>, discusses the phase 3 SYMPATICO trial examining the combination of ibrutinib and venetoclax vs ibrutinib alone in patients with relapsed or refractory mantle cell lymphoma #lymsm bit.ly/3tk0h5v